|
|
|
| Clinical effect of modified Linggui Zhugan Decoction combined with Metformin in the treatment of obesity type 2 diabetes mellitus with phlegm-dampness syndrome#br# |
| LUO Li1 LIU Chungu1 HUANG Yu2 ZHANG Zhenyu2 YU Yaohe1 LONG Shuni1 |
1.Department of Traditional Chinese Medicine, Guangzhou Xinhai Hospital, Guangdong Province, Guangzhou 510300, China;
2.Department of Endocrinology, Guangzhou Xinhai Hospital, Guangdong Province, Guangzhou 510300, China |
|
|
|
Abstract Objective To observe the clinical effect of modified Linggui Zhugan Decoction combined with Metformin in the treatment of obesity type 2 diabetes mellitus (T2DM) with phlegm-dampness syndrome. Methods Seventy obesity T2DM patients with phlegm-dampness syndrome in Guangzhou Xinhai Hospital from February 2018 to May 2021 were selected and divided into control group and experimental group by random number table method, with 35 cases in each group. All patients were treated with health education and lifestyle intervention. The control group were treated with Metformin, and the experimental group were treated with modified Linggui Zhugan Decoction combined with Metformin. Both groups were treated for six weeks. The changes of body mass index (BMI), waist-to-hip ratio (WHR), fasting blood glucose (FPG), 2 hours postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) in two groups were compared before and after treatment, and the clinical efficacy of the two groups was evaluated. Results After treatment, BMI, WHR, FPG, 2hPG, HbA1c, TG, and LDL-C in two groups were lower than before treatment, and FPG, 2hPG, HbA1c, TG, and LDL-C in the experimental group were lower than those in the control group (P ＜ 0.05). After treatment, the clinical effect of the experimental group was better than the control group (P ＜ 0.05). Conclusion The clinical efficacy of modified Linggui Zhugan Decoction combined with Metformin in the treatment of obesity T2DM patients with phlegm-dampness syndrome is superior to that of Metformin alone, and it has advantages in regulating glucolipid metabolism disorder, which is worthy of clinical promotion.
|
|
|
|
|
|
[1] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）[J].中华糖尿病杂志，2021，13（4）：315-409.
[2] 宁光.中国糖尿病防治的现状及展望[J].中国科学：生命科学，2018，48（8）：810-811.
[3] 李冀，车思桦，关迪新，等.2型糖尿病胰岛素抵抗机制及中医药治疗研究[J].辽宁中医药大学学报，2019，21（11）：5-8.
[4] 邹大进.肥胖相关性2型糖尿病治疗新进展[J].中国科学：生命科学，2018，48（8）：872-875.
[5] 赵蕾，郭志芹.2型糖尿病合并肥胖的中医证候分型特点研究[J].中医临床研究，2019，11（1）：4-7.
[6] 金昕，王静懿，杨雪蓉，等.灵芪参口服液改善2型糖尿病（气阴两虚证）糖代谢和胰岛素抵抗的临床研究[J].上海中医药杂志，2020，54（S1）：50-54.
[7] 王宾，柳红芳，李多多，等.臧氏振腹减脂术治疗单纯性肥胖伴血脂异常的疗效观察[J].中华中医药杂志，2020， 35（4）：2156-2158.
[8] 宛金，周莎，王彦晖，等.王彦晖运用健脾补气法治疗肥胖病经验解析[J].中华中医药杂志，2019，34（4）：1517-1520.
[9] 颜新林，韩星星，陆峰，等.中西医结合治疗肥胖2型糖尿病概况[J].河南中医，2019，39（10）：1615-1620.
[10] 葛均波，徐永健，王辰，等.内科学[M].9版.北京：人民卫生出版社，2018：733-734.
[11] 中华人民共和国卫生部疾病控制司.中国成人超重和肥胖症预防控制指南[S].北京：人民卫生出版社，2008：3-4.
[12] 薛博瑜，吴伟.中医内科学[M].3版.北京：人民卫生出版社，2020：332-337.
[13] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：233-237.
[14] 尚祥岭.健脾降糖汤治疗肥胖型2型糖尿病痰瘀气虚证临床研究[J].中医学报，2017，32（5）：743-746.
[15] 张倩，宋玮，梁晓春.代谢组学在糖尿病及其中医药干预研究中的应用[J].中国中西医结合杂志，2021，41（1）：116-121.
[16] Verges B. Pathophysiology of diabetic dyslipidaemia：where are we [J]. Diabetologia，2015，58（5）：886-899.
[17] Aon MA，Bhatt N，Cortassa SC. Mitochondrial and cellular mechanisms for managing lipid excess [J]. Front Physiol，2014，5（13）：282.
[18] 焦倩，黎艳，袁早送，等.初诊2型糖尿病患者血浆Alarin水平及其与糖脂代谢、胰岛素抵抗的关系[J].广西医学，2019，41（23）：2961-2964.
[19] 王冬香，于建锋，彭飞，等.中医辨证治疗2型糖尿病的临床分析[J].糖尿病新世界，2020，23（20）：87-89.
[20] 王翔，施慧，黄金玲.近10年苓桂术甘汤研究热点、研究趋势的知识图谱分析[J].时珍国医国药，2019，30（8）：2008-2010.
[21] 夏城东.2型糖尿病中医药治疗的脏腑归属[J].中国中西医结合杂志，2021，41（6）：748-751.
[22] 罗辉，王琦.中医体质与疾病相关性临床研究的方法学挑战和设计实施建议[J].中医杂志，2020，61（1）：20-26.
[23] 罗辉，王琦.中医体质类型与代谢综合征相关性研究的系统评价和Meta分析[J].北京中医药大学学报，2016， 39（4）：325-334.
[24] 倪靖怡，李旷怡，张英俭，等.加味苓桂术甘汤对代谢综合征大鼠脂肪细胞因子和骨骼肌葡萄糖转运蛋白表达的影响[J].广州中医药大学学报，2020，37（9）：1769-1774.
[25] 师林，杨玉彬，黄颖娟，等.健脾化湿方对脾虚痰湿型肥胖2型糖尿病胰岛素抵抗大鼠骨骼肌PI3K/Akt通路的影响[J].中华中医药杂志，2018，33（2）：530-534. |
|
|
|
